The Insider, Jamie Grooms Unloaded 63,395 Shares of AxoGen, Inc. (AXGN); Shorts at ALFA-LAVAL AB ORDINARY SHARES SWEDEN (ALFVF) Raised By 4.18%

February 21, 2018 - By Peter Erickson

ALFA-LAVAL AB ORDINARY SHARES SWEDEN (OTCMKTS:ALFVF) had an increase of 4.18% in short interest. ALFVF’s SI was 580,300 shares in February as released by FINRA. Its up 4.18% from 557,000 shares previously. The SI to ALFA-LAVAL AB ORDINARY SHARES SWEDEN’s float is 0.2%. It closed at $23.54 lastly. It is down 0.00% since February 21, 2017 and is . It has underperformed by 16.70% the S&P500.

An insider of the company Axogen Inc, Jamie Grooms also its director, disclosed her well-informed sell activities with the U.S. Security & Exchange Commission on February 20, 2018. As stated in the document, Jamie had sold 63,395 shares of the Florida-based Axogen Inc. The total insider trading trade was worth $1,754,060 U.S. Dollars. At the time of the trade the price of a share was $27.7. This is not her first insider trade, in the last month, she sold another 191,424 shares worth $5,137,938 USD. This massive deal will probably draw attention, as Jamie Grooms presently owns 0.18% of the total market cap of Axogen Inc.

Alfa Laval AB provides heat transfer, separation, and fluid handling products and solutions for use in various industries worldwide. The company has market cap of $9.87 billion. The firm operates in three divisions: Equipment, Process Technology, and Marine & Diesel. It has a 26.45 P/E ratio. The Company’s fluid handling systems include automation equipment; fluid control equipment; installation materials; analytical instruments; analytical, cleaning validation, flow, level, pressure, temperature, and weighing instruments, as well as instrumentation accessories; mixing equipment; centrifugal, circumferential piston, rotary lobe, and screw pumps; rotary jet and spray heads; tank cover and accessories; and valves.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $946.10 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen has $37.0 highest and $4 lowest target. $23.50’s average target is -15.32% below currents $27.75 stock price. AxoGen had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Hold” on Tuesday, August 11. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, November 21 report. As per Monday, September 11, the company rating was maintained by Roth Capital. The rating was maintained by Wedbush with “Outperform” on Friday, August 28. Leerink Swann maintained it with “Outperform” rating and $26 target in Thursday, November 2 report. The firm earned “Buy” rating on Tuesday, November 21 by Wedbush. The firm has “Hold” rating given on Thursday, November 3 by Lake Street. Wedbush maintained AxoGen, Inc. (NASDAQ:AXGN) on Monday, November 7 with “Outperform” rating. Cantor Fitzgerald maintained the stock with “Buy” rating in Monday, January 8 report. The firm earned “Buy” rating on Monday, August 21 by Cantor Fitzgerald.

The stock increased 1.28% or $0.35 during the last trading session, reaching $27.75. About 267,205 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since February 21, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Erickson

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: